S-Nitrosylated hemoglobin predicts organ yield in neurologically-deceased human donors

Ryan Nazemian1,2, Maroun Matta1,3, Amer Aldamouk1,2, Lin Zhu1,2, Mohamed Awad1,2, Megan Pophal1, Nicole R. Palmer1,2, Tonya Armes1, Alfred Hausladen1,4, Jonathan S. Stamler1,4,5 & James D. Reynolds1,2,5

Current human donor care protocols following death by neurologic criteria (DNC) can stabilize macro-hemodynamic parameters but have minimal ability to preserve systemic blood flow and microvascular oxygen delivery. S-nitrosylated hemoglobin (SNO-Hb) within red blood cells (RBCs) is the main regulator of tissue oxygenation (StO2). Based on various pre-clinical studies, we hypothesized that brain death (BD) would decrease post-mortem SNO-Hb levels to negatively impact StO2 and reduce organ yields. We tracked SNO-Hb and tissue oxygen in 61 DNC donors. After BD, SNO-Hb levels were determined to be significantly decreased compared to healthy humans (p = 0.003) and remained reduced for the duration of the monitoring period. There was a positive correlation between SNO-Hb and StO2 (p < 0.001). Furthermore, SNO-Hb levels correlated with and were prognostic for the number of organs transplanted (p < 0.001). These clinical findings provide additional support for the concept that BD induces a systemic impairment of S-nitrosylation that negatively impacts StO2 and reduces organ yield from DNC human donors. Exogenous S-nitrosylating agents are in various stages of clinical development. The results presented here suggest including one or more of these agents in donor support regimens could increase the number and quality of organs available for transplant.

Surgical and immunological techniques have advanced significantly since the first successful solid organ transplant was conducted in 1954. What has not kept pace is/are the evolution of procedures and interventions used to systemically-support the deceased by neurologic criteria (DNC) donor1–6. And yet it is becoming very obvious that the functional status of gifted organs at the time of procurement is/are very important to the success of both short and long-term post-graft function7. In this regard, we have raised the idea that disorders in organ function are a reflection of systemic physiologic failure not the result of disparate organs responding to the loss of central nervous system (CNS) regulation8,9. Specifically, that systemic organ failure may be due to disruptions in microvascular tissue oxygen delivery.

While DNC donor care protocols have been standardized throughout the UNOS and OPO networks, they are almost exclusively directed towards stabilizing macro-hemodynamic parameters. A consequence of this limited focus is that commonly used interventions (e.g. increasing FiO2; administration of vasopressors) may benefit some organs at the costs of damaging others (viz. lung and heart, respectively). No current intervention or donor support methodology specifically targets the microvascular circulation even as it is tissue oxygenation not blood oxygen saturation that impacts systemic organ function. Local tissue perfusion is regulated by a physiological response termed hypoxic vasodilation in which tissue oxygen requirements are directly coupled to blood flow, the domain of nitric oxide (NO) bioactivity10,11. Within red blood cells (RBCs), hemoglobin (Hb) serves as an oxygen sensor and as a hypoxia-responsive transducer of NO signals, which couples blood flow to...
tissue oxygen requirements. In particular, vasodilation by S-nitrosylated-Hb (SNO-Hb; i.e. release of NO bioactivity) is linked to Hb desaturation and thus provides a regulated mechanism that matches blood flow and oxygen delivery to local metabolic demand. Decreased levels of SNO-Hb have been observed in a disparate collection of human diseases characterized by tissue hypoxemia. Such findings suggest that RBC-derived NO bioactivity plays an important role in the respiratory cycle and that impairment of this activity contributes to the pathophysiology of ischemic conditions, including BD. In a translational pre-clinical study utilizing swine, we confirmed that BD resulted in reduced circulating levels of SNO-Hb, reductions in microvascular tissue oxygenation (StO2), and declines in systemic organ function. We followed this with a study of DNC donors where we determined that StO2, but not arterial blood oxygenation (SaO2; a macrohemodynamic parameter), was directly correlated with transplantable organ yield. In this current report, we link the two findings by showing SNO-Hb levels correlate directly with StO2 and with subsequent organ yield. The importance of this relationship lies in the fact that SNO-Hb is a druggable target and we have clinically-tested S-nitrosylating agents that can raise SNO-Hb levels, supporting the concept that such interventions could be used to increase the number and functional status of solid organs procured from DNC donors.

Results
Demographics. We enrolled 61 DNC donors in this study. Two subjects were excluded from the final data set due to diagnosed communicable systemic infections that prevented organ utilization and whose blood samples the research laboratory was not equipped to safely process as part of the SNO-Hb analysis. Donor demographic, physiologic data, and procurement outcomes are presented in Table 1. As a group, the subjects were well-ventilated and overall hemodynamically-stable as evidenced by constant levels of vasopressor requirement during the support phase and stable ventilator parameters and P/F ratios.

RBC SNO-Hb and tissue oxygen saturation during donor support. As predicted from our pre-clinical work, we found that total RBC HbNO levels were significantly decreased in the DNC donors compared to the concentrations quantified in arterial blood aliquots obtained from a group of healthy humans (Fig. 1a;
This reduction was completely accounted for by major declines in SNO-Hb (grey columns) for the duration of the sampling period with little to no change in the circulating amounts of FeNO-Hb (black columns). Within the DNC group, there were variations in the SNO-Hb concentrations that were directly correlated to differences in StO2 (Cor. Coef. 1.09, r = 0.44, Fig. 1b), i.e. lower SNO-Hb levels were associated with lower measures of tissue oxygenation consistent with the major role played by RBC-derived NO-bioactivity in regulating microvascular blood flow and oxygen delivery. Furthermore, there was a negative correlation between SNO-Hb levels and the duration of donor support (Cor. Coef. 0.98, r = −0.39, Fig. 1c). Additionally, we did not observe any statistically significant correlation between duration of support phase and number of organs transplanted.

**Relationship between SNO-Hb and organ yield.** With a link previously established between StO2 and organ yield, and the current findings of a correlation between StO2 and SNO-Hb levels, we next analyzed the relationship between SNO-Hb and procurement of organs deemed suitable for transplant. In univariate models, as a whole, we determined there was a direct correlation between SNO-Hb and the number of trans-
planted organs (Cor. Coef. 1.05, r = 0.12, Fig. 2a). This positive relationship was strengthened when the ordinate was replaced with the expected number of transplanted organs (calculated by UNOS criteria) while keeping the abscissa as donor SNO-Hb levels (Cor. Coef. 1.39, r = −0.24, Fig. 2b). The overall relationship was further strengthened by determining that the concentrations of SNO-Hb inversely correlated with the number of organs deemed unsuitable for transplant at the end of the donor support period (Cor. Coef. 0.87, r = −0.13, p < 0.05).

In multivariate models, adjusting for SNO-Hb, age and BMI, the correlation remained statistically significant (p < 0.05). As noted in the methods, the SNO-Hb analysis and tissue oxygenation calculations were conducted off-line so neither changes in RBC-derived NO bioactivity nor StO2 factored into the procurement teams’ decisions regarding organ utilization or rejection.

**Discussion**

Transplantation is an accepted intervention to correct innate organ failure, but current replacement needs greatly outpace organ availability. Significant societal benefit would result from increasing the number of organs available for transplant. Unfortunately, donation rates for deceased donors have been static for several years despite various public education campaigns. While it is true that the proportion and number of living donors has increased, this latter group is limited to kidneys and livers and still only makes up a small percentage of the overall donor pool. Further exacerbating this situation is that the number of organs recovered per donor is far less than 100%. Optimizing donor status is an obvious (if underutilized) strategy to increase the number of transplantable organs.

**Figure 2.** Association between amount of SNO-Hb and (a) number of organs transplanted, and (b) expected organs with Poisson regression model.
SaO2 stayed constant). Other work has demonstrated acute oxygenation benefits in distinct clinical populations, including infants with persistent pulmonary hypertension of the newborn and adults newly diagnosed with idiopathic pulmonary arterial hypertension. Of direct relevance to the current study, we recently determined that addition of ENO to the preservation solution of pumped human kidneys (procured but subsequently during storage were deemed unsuitable for transplant) restored cellular SNO tissue status, reduced markers of inflammation, and improved perfusion parameters to transplantable levels.

The significance of these findings is two-fold:

1. disruptions in SNO homeostasis continue into the ex vivo storage/transport phase; and
2. exogenous S-nitrosylation therapy could provide functional benefits both during and after the whole-body donor support phase.

At the same time, it needs to be emphasized that predicting transplant success based upon pre-procurement SNO activity is premature. There are a variety of ex vivo storage and treatment strategies that may or may not correct SNO deficits. These include static versus active storage, hypothermic versus normothermic storage conditions, and “revitalization” interventions immediately prior to engraftment. As a result, we have deliberately limited the present results to procurement of organs deemed suitable for transplant (even as we actively explore the therapeutic potential of ex vivo interventions to improve organ status).

In conclusion, we provide clinical evidence for the concept that BD induces a systemic impairment of S-nitrosylation that negatively impacts StO2 and reduces organ yield from DNC human donors. Currently, S-nitrosylating agents are undergoing clinical testing to correct oxygenation pathologies. This specific type of directed intervention has the potential to increase the quantity and quality of organs available for transplant and ultimately improve the outcome of transplant recipients.

Materials and methods

Study population. This prospective observational study replicated the design of our previous monitoring trial. The target population was consented DNC organ donors ≥ 15 years of age and weighing ≥ 45 kg. Living donors and individuals declared deceased after circulatory determination of death were not studied. The study protocol was cleared by the Institutional Review Board of University Hospitals-Cleveland Medical Center, an AAHRPP-accredited institution, as non-living subjects research. In addition, the donor study was approved by the Medical Advisory Board and the Board of Directors of the local organ procurement organization for Northeast Ohio (Lifebanc; Cleveland, OH). Authorization for research participation was obtained by either pre-morbid first-person informed consent or from the donor’s next-of-kin as a component of the organ donation informed consent process. The procurement of blood samples from healthy subjects was covered under a human studies protocol approved by the UH-CMC IRB. Written informed consent was obtained from each living individual prior to their voluntary participation in the study. All experiments on living subjects were performed in accordance with relevant guidelines and regulations. Based on our previous monitoring trial, we determined a sample size projection of 60 donors would yield 90% power to detect a clinically meaningful difference in organ yield. We included all eligible DNC organs from 2015 to 2018 in the study.
Study protocol. Research personnel were contacted about eligible subjects by the Lifebanc donor management team; blood sampling and monitoring was initiated as soon as possible after obtaining of donor consent. Arterial blood sample were obtained from existing vascular monitoring lines at 6–12 h intervals. Tissue oxygenation (StO₂) was recorded from the thenar eminence using a NIRS probe (Hutchinson Technology Inc; Hutchinson, MN). The StO₂ values were not used to influence donor management though the care team was instructed on how to reattach the probe in case of accidental displacement. Sampling and monitoring were continued up until the point of organ retrieval. In living human volunteers, arterial blood samples were obtained by needle puncture or following placement of avascular access catheter by suitably trained physicians. In both settings, lidocaine was used to provide local pain control; no adverse events occurred. The procured blood was then processed similar to samples obtained from the DNC donor cohort.

Clinical chemistry and other measurements. Blood gas parameters were measured using an IRMA TruPoint Blood Analysis System (LifeHealth; Roseville, MN). SNO-Hb and FeNO-Hb (defined as biologically inert heme-bound NO) levels were quantified using mercury-coupled photolysis chemiluminescence; each sample was assayed in triplicate. Additional blood chemistries were measured by the core clinical laboratory of the supporting hospital. Donor demographics, physiologic status, organ retrieval numbers, and interventions conducted during the management phase were collected post-hoc from the subjects’ medical records. Number of organs expected were based on the OPTN-SRTR “Organ Yield Calculator”.

Data analysis. For continuous parameters (viz. StO₂), medians were calculated at 1-h intervals and area under the curve values were compared. Quantitative variables are presented as means ± standard deviations (SDs) for normally distributed data and median with inter-quartile ranges (IQRs) for non-normally distributed data are reported.

For comparisons, T-test and Wilcoxon–Mann–Whitney test were used for quantitative data. For qualitative variables, Chi-Square and Fisher exact tests were employed. Longitudinal analyses of repeated–measured data were done by linear mixed model with the assumption of missing data at random. For determining association between variables and the count outcome, Poisson regression modeling was implemented. For assessing linear correlations between continuous variables, the average value of each variable during recovery phase was used and Pearson method was employed. All data were analyzed with latest version of R statistical software (4·0·3). Statistically significant differences were presumed when p < 0.05.

Received: 25 June 2021; Accepted: 9 March 2022
Published online: 22 April 2022

References
1. Robba, C., Iaquaniello, C. & Citerio, G. Death by neurologic criteria: Pathophysiology, definition, diagnostic criteria and tests. Minerva Anestesiol. 85(7), 774–781 (2019).
2. Souter, M. J. et al. Organ donor management: Part 1. Toward a consensus to guide anesthesia services during donation after brain death. Semin. Cardiothorac. Vasc. Anesth. 22(2), 211–222 (2018).
3. Souter, M. J. & Kirsch, M. Brain death: Optimizing support of the traumatic brain injury patient awaiting organ procurement. Crit. Care. 26(2), 153–161 (2020).
4. Niemann, C. U., Matthay, M. A. & Ware, L. B. The continued need for clinical trials in deceased organ donor management. Transplantation 103(7), 1298–1299 (2019).
5. Manara, A., Procaccio, F. & Dominguez-Gil, B. Expanding the pool of deceased organ donors: The ICU and beyond. Intensive Care Med. 45(3), 357–360 (2019).
6. UNOS. National Trends in Organ Transplant: https://optn.transplant.hrsa.gov/data/ (accessed May 2021).
7. Resch, T. et al. Transplanting marginal organs in the era of modern machine perfusion and advanced organ monitoring. Front. Immunol. 11, 631 (2020).
8. Shutter, L. Pathophysiology of brain death: What does the brain do and what is lost in brain death? J. Crit. Care. 29(4), 683–686 (2014).
9. Truong, R. D., Paquette, E. T. & Tasker, R. C. Understanding brain death. JAMA 323(21), 2139–2140 (2020).
10. Premont, R. T., Reynolds, J. D., Zhang, R. & Stamler, J. S. Role of nitric oxide carried by hemoglobin in cardiovascular physiology: Developments on a three-gas respiratory cycle. Circ. Res. 126(1), 129–158 (2020).
11. Premont, R. T., Reynolds, J. D., Zhang, R. & Stamler, J. S. Red blood cell-mediated S-nitrosohemoglobin-dependent vasodilation: Lessons learned from a beta-globin Cys93 knock-in mouse. Antioxid. Redox Signal. 34(12), 936–961 (2021).
12. Ia, L., Bonaventura, C., Bonaventura, J. & Stamler, J. S. S-nitrosohemoglobin: A dynamic activity of blood involved in vascular control. Nature 380(6571), 221–226 (1996).
13. Zhang, R. et al. Hemoglobin betaCy593 is essential for cardiovascular function and integrated response to hypoxia. Proc. Natl. Acad. Sci. U. S. A. 112(20), 6425–6430 (2015).
14. Yurchisin, B. M. et al. Repletion of S-nitrosohemoglobin improves organ function and physiological status in swine after brain death. Ann. Surg. 257(5), 971–977 (2013).
15. Perez-Prosto, S. E. et al. Peripheral tissue oxygenation and the number of organs transplanted per donor. Anaesth. Intensive Care. 46(6), 601–607 (2018).
16. Lee, L. Y., Pham, T. A. & Melcher, M. L. Living kidney donation: Strategies to increase the donor pool. Surg. Clin. N. Am. 99(1), 37–47 (2019).
17. Liu, L. et al. Essential roles of S-nitrosothiols in vascular homeostasis and endotoxic shock. Cell 116(4), 617–628 (2004).
18. Jensen, F. B. The dual roles of red blood cells in tissue oxygen delivery: Oxygen carriers and regulators of local blood flow. J. Exp. Biol. 212( Pt 21), 3387–3393 (2009).
19. Reynolds, J. D. et al. Pharmacologic targeting of red blood cells to improve tissue oxygenation. Clin. Pharmacol. Ther. 104(3), 553–563 (2018).
20. Zhou, H. L. et al. A novel method to improve perfusion of ex vivo pumped human kidneys. Ann. Surg. 274(6), e610–e615 (2021).
21. Zhou, H. L. et al. Metabolic reprogramming by the S-nitroso-CoA reductase system protects against kidney injury. Nature 565(7773), 96–100 (2019).
22. McMahon, T. J. et al. Nitric oxide in the human respiratory cycle. Nat. Med. 8(7), 711–717 (2002).
23. McMahon, T. J. et al. A nitric oxide processing defect of red blood cells created by hypoxia: Deficiency of S-nitrosohemoglobin in pulmonary hypertension. Proc. Natl. Acad. Sci. U. S. A. 102(41), 14801–14806 (2005).
24. Hausladen, A. et al. Assessment of nitric oxide signals by triiodide chemiluminescence. Proc. Natl. Acad. Sci. U. S. A. 104(7), 2157–2162 (2007).
25. Diers, A. R., Keszler, A. & Hogg, N. Detection of S-nitrosothiols. Biochim. Biophys. Acta. 1840(2), 892–900 (2014).

Acknowledgements
The authors gratefully thank the donors and donor families for gifting the deceaseds’ organs for transplant and authorizing participation in this study. The authors also thank the staff at Lifebanc for their expert assistance with conducting the monitoring and compiling the clinical data.

Author contributions
This was a multi-departmental endeavor that required coordination, effort, and input from several individuals. With respect to specific contributions: J.D.R. conceived the study; J.D.R. designed the research studies in consultation with R.N., M.M., A.A., and J.S.S.; R.N., M.M., A.A., and M.A. conducted the donor monitoring; R.N., A.A., L.Z., M.A., M.P., N.R.P., T.A., and A.H. conducted the blood sample analyses; R.N., M.M., A.A., M.A., L.Z., and A.H. collated and analyzed the data; R.N. and J.D.R. wrote the manuscript with critical insights provided by J.S.S.; A.H. contributed new reagents/analytical tools; and all authors provided editorial input to the final submission.

Funding
This work was supported in part by grants from the Roche Organ Transplant Research Foundation (Meggen, Switzerland; Grant #61800655), the AHA-Allen Brain Health Initiative (19PABHI34580006), the Eppley Foundation (New York, NY) Enduring Hearts (Marietta, GA), and Additional Ventures (Palo Alto, CA), as well as by contract W81XWH-16-1-0520 from the US Army Medical Research and Materiel Command.

Competing interests
Drs. Stamler and Reynolds hold patents related to renitrosylation, some of which may be licensed for commercial development. In addition, Dr. Stamler has an equity interest in SNO Bio, a company developing nitrosylation related therapeutics. Their institutions are aware of these potential conflicts and appropriate management plans are in place. None of the other authors have relevant conflicts to disclose.

Additional information
Correspondence and requests for materials should be addressed to J.D.R.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022